Literature DB >> 7658272

Lethal neonatal deficiency of carnitine palmitoyltransferase II associated with dysgenesis of the brain and kidneys.

K N North1, C L Hoppel, U De Girolami, H P Kozakewich, M S Korson.   

Abstract

We describe neonatal onset of a lethal multiorgan deficiency of carnitine palmitoyltransferase II (CPT II) associated with dysmorphic features, cardiomyopathy, and cystic dysplasia of the brain and kidneys. Concentrations of long-chain acylcarnitines were evaluated in blood and multiple tissues, diffuse lipid accumulation was present at autopsy, and a profound deficiency of CPT II activity was evident in heart, liver, muscle, and kidney tissue. This disorder constitutes another recognizable malformation syndrome with a metabolic basis. Deficiency of CPT II should be included in the differential diagnosis of patients with cystic renal dysplasia, dysmorphism, central nervous system malformations, and early death, along with glutaric acidemia type II, Zellweger syndrome, and other disorders in which peroxisomal beta-oxidation is impaired. The clinicopathologic similarities among these disorders raise the possibility that a common biochemical mechanism, namely the disruption of beta-oxidation of fatty acids, is responsible for the abnormal organogenesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7658272     DOI: 10.1016/s0022-3476(95)70073-0

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  17 in total

Review 1.  Delineating the role of alterations in lipid metabolism to the pathogenesis of inherited skeletal and cardiac muscle disorders: Thematic Review Series: Genetics of Human Lipid Diseases.

Authors:  Harjot K Saini-Chohan; Ryan W Mitchell; Frédéric M Vaz; Teresa Zelinski; Grant M Hatch
Journal:  J Lipid Res       Date:  2011-11-07       Impact factor: 5.922

2.  Inhibition of β-oxidation is not a valid therapeutic tool for reducing oxidative stress in conditions of neurodegeneration.

Authors:  Peter Schönfeld; Georg Reiser
Journal:  J Cereb Blood Flow Metab       Date:  2016-07-20       Impact factor: 6.200

3.  Carnitine palmitoyltransferase II deficiency: diagnosis by molecular analysis of blood.

Authors:  P Kaufmann; M el-Schahawi; S DiMauro
Journal:  Mol Cell Biochem       Date:  1997-09       Impact factor: 3.396

4.  Neonatal carnitine palmitoyltransferase II deficiency: failure of treatment despite prolonged survival.

Authors:  Petra Hissink-Muller; Enrico Lopriore; Carolien Boelen; Frans Klumper; Marinus Duran; Frans Walther
Journal:  BMJ Case Rep       Date:  2009-06-26

Review 5.  Metabolic cardiomyopathies.

Authors:  B Guertl; C Noehammer; G Hoefler
Journal:  Int J Exp Pathol       Date:  2000-12       Impact factor: 1.925

Review 6.  On the molecular etiology of decreased arachidonic (20:4n-6), docosapentaenoic (22:5n-6) and docosahexaenoic (22:6n-3) acids in Zellweger syndrome and other peroxisomal disorders.

Authors:  J P Infante; V A Huszagh
Journal:  Mol Cell Biochem       Date:  1997-03       Impact factor: 3.396

Review 7.  Defects in activation and transport of fatty acids.

Authors:  M Brivet; A Boutron; A Slama; C Costa; L Thuillier; F Demaugre; D Rabier; J M Saudubray; J P Bonnefont
Journal:  J Inherit Metab Dis       Date:  1999-06       Impact factor: 4.982

8.  Cerebral Lipid Accumulation Detected by MRS in a Child with Carnitine Palmitoyltransferase 2 Deficiency: A Case Report and Review of the Literature on Genetic Etiologies of Lipid Peaks on MRS.

Authors:  Carlos R Ferreira; Molly H Silber; Taeun Chang; Jonathan G Murnick; Brian Kirmse
Journal:  JIMD Rep       Date:  2015-11-05

9.  Cystic renal dysplasia as a leading sign of inherited metabolic disease.

Authors:  Felix Distelmaier; Markus Vogel; Ute Spiekerkötter; Klaus Gempel; Dirk Klee; Stefan Braunstein; Heinz-Peter Groneck; Ertan Mayatepek; Udo Wendel; Bernd Schwahn
Journal:  Pediatr Nephrol       Date:  2007-07-19       Impact factor: 3.714

10.  Renal mitochondrial cytopathies.

Authors:  Francesco Emma; Giovanni Montini; Leonardo Salviati; Carlo Dionisi-Vici
Journal:  Int J Nephrol       Date:  2011-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.